FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379600227> ?p ?o ?g. }

• W4379600227 endingPage "3445" @default.
• W4379600227 startingPage "3434" @default.
• W4379600227 abstract "To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Chinese patients with type 2 diabetes (T2D).In this phase 1, double-blind, placebo-controlled, multiple dose study, patients were randomized into one of two cohorts to receive once-weekly subcutaneous tirzepatide or placebo. The initial tirzepatide dose in both cohorts was 2.5 mg, which was increased by 2.5 mg every 4 weeks to a maximum final dose of 10.0 mg at week 16 (Cohort 1) or 15.0 mg at week 24 (Cohort 2). The primary outcome was the safety and tolerability of tirzepatide.Twenty-four patients were randomized (tirzepatide 2.5-10.0 mg: n = 10, tirzepatide 2.5-15.0 mg: n = 10, placebo: n = 4); 22 completed the study. The most frequently reported treatment-emergent adverse events (TEAEs) among patients receiving tirzepatide were diarrhea and decreased appetite; most TEAEs were mild and resolved spontaneously with no serious adverse events reported in the tirzepatide groups and one in the placebo group. The plasma concentration half-life of tirzepatide was approximately 5-6 days. Mean glycated hemoglobin (HbA1c) decreased over time from baseline in the 2.5-10.0 mg (- 2.4%) and 2.5-15.0 mg (- 1.6%) tirzepatide groups, at week 16 and week 24, respectively, but remained steady in patients receiving placebo. Body weight decreased from baseline by - 4.2 kg at week 16 in the tirzepatide 2.5-10.0 mg group and by - 6.7 kg at week 24 in the 2.5-15.0 mg group. Mean fasting plasma glucose levels fell from baseline by - 4.6 mmol/L in the tirzepatide 2.5-10.0 mg group at week 16 and by - 3.7 mmol/L at week 24 in the tirzepatide 2.5-15.0 mg group.Tirzepatide was well tolerated in this population of Chinese patients with T2D. The safety, tolerability, PK, and PD profile of tirzepatide support once-weekly dosing in this population.ClinicalTrials.gov: NCT04235959." @default.
• W4379600227 created "2023-06-08" @default.
• W4379600227 creator A5002041682 @default.
• W4379600227 creator A5008296751 @default.
• W4379600227 creator A5031510744 @default.
• W4379600227 creator A5037101612 @default.
• W4379600227 creator A5041956749 @default.
• W4379600227 creator A5055366448 @default.
• W4379600227 creator A5061303769 @default.
• W4379600227 creator A5070339370 @default.
• W4379600227 creator A5089116496 @default.
• W4379600227 date "2023-06-07" @default.
• W4379600227 modified "2023-10-18" @default.
• W4379600227 title "A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes" @default.
• W4379600227 cites W2790574529 @default.
• W4379600227 cites W2895135221 @default.
• W4379600227 cites W2895666357 @default.
• W4379600227 cites W2984893157 @default.
• W4379600227 cites W3004172664 @default.
• W4379600227 cites W3087889571 @default.
• W4379600227 cites W3093042356 @default.
• W4379600227 cites W3177122952 @default.
• W4379600227 cites W3177393241 @default.
• W4379600227 cites W3191712049 @default.
• W4379600227 cites W3205201678 @default.
• W4379600227 cites W3206180121 @default.
• W4379600227 cites W4200230313 @default.
• W4379600227 cites W4210940103 @default.
• W4379600227 cites W4226150887 @default.
• W4379600227 cites W4247704066 @default.
• W4379600227 cites W4280579438 @default.
• W4379600227 cites W4288735703 @default.
• W4379600227 cites W4288740467 @default.
• W4379600227 doi "https://doi.org/10.1007/s12325-023-02536-8" @default.
• W4379600227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37285081" @default.
• W4379600227 hasPublicationYear "2023" @default.
• W4379600227 type Work @default.
• W4379600227 citedByCount "0" @default.
• W4379600227 crossrefType "journal-article" @default.
• W4379600227 hasAuthorship W4379600227A5002041682 @default.
• W4379600227 hasAuthorship W4379600227A5008296751 @default.
• W4379600227 hasAuthorship W4379600227A5031510744 @default.
• W4379600227 hasAuthorship W4379600227A5037101612 @default.
• W4379600227 hasAuthorship W4379600227A5041956749 @default.
• W4379600227 hasAuthorship W4379600227A5055366448 @default.
• W4379600227 hasAuthorship W4379600227A5061303769 @default.
• W4379600227 hasAuthorship W4379600227A5070339370 @default.
• W4379600227 hasAuthorship W4379600227A5089116496 @default.
• W4379600227 hasBestOaLocation W43796002271 @default.
• W4379600227 hasConcept C111113717 @default.
• W4379600227 hasConcept C112705442 @default.
• W4379600227 hasConcept C126322002 @default.
• W4379600227 hasConcept C134018914 @default.
• W4379600227 hasConcept C142724271 @default.
• W4379600227 hasConcept C197934379 @default.
• W4379600227 hasConcept C204787440 @default.
• W4379600227 hasConcept C27081682 @default.
• W4379600227 hasConcept C2777180221 @default.
• W4379600227 hasConcept C2777538456 @default.
• W4379600227 hasConcept C2778375690 @default.
• W4379600227 hasConcept C555293320 @default.
• W4379600227 hasConcept C71924100 @default.
• W4379600227 hasConcept C72563966 @default.
• W4379600227 hasConcept C90924648 @default.
• W4379600227 hasConceptScore W4379600227C111113717 @default.
• W4379600227 hasConceptScore W4379600227C112705442 @default.
• W4379600227 hasConceptScore W4379600227C126322002 @default.
• W4379600227 hasConceptScore W4379600227C134018914 @default.
• W4379600227 hasConceptScore W4379600227C142724271 @default.
• W4379600227 hasConceptScore W4379600227C197934379 @default.
• W4379600227 hasConceptScore W4379600227C204787440 @default.
• W4379600227 hasConceptScore W4379600227C27081682 @default.
• W4379600227 hasConceptScore W4379600227C2777180221 @default.
• W4379600227 hasConceptScore W4379600227C2777538456 @default.
• W4379600227 hasConceptScore W4379600227C2778375690 @default.
• W4379600227 hasConceptScore W4379600227C555293320 @default.
• W4379600227 hasConceptScore W4379600227C71924100 @default.
• W4379600227 hasConceptScore W4379600227C72563966 @default.
• W4379600227 hasConceptScore W4379600227C90924648 @default.
• W4379600227 hasFunder F4320307758 @default.
• W4379600227 hasIssue "8" @default.
• W4379600227 hasLocation W43796002271 @default.
• W4379600227 hasLocation W43796002272 @default.
• W4379600227 hasLocation W43796002273 @default.
• W4379600227 hasOpenAccess W4379600227 @default.
• W4379600227 hasPrimaryLocation W43796002271 @default.
• W4379600227 hasRelatedWork W1830687917 @default.
• W4379600227 hasRelatedWork W1934667138 @default.
• W4379600227 hasRelatedWork W1966047811 @default.
• W4379600227 hasRelatedWork W2003042623 @default.
• W4379600227 hasRelatedWork W202460821 @default.
• W4379600227 hasRelatedWork W2074207917 @default.
• W4379600227 hasRelatedWork W2090169689 @default.
• W4379600227 hasRelatedWork W2538072326 @default.
• W4379600227 hasRelatedWork W2765994429 @default.
• W4379600227 hasRelatedWork W4298086959 @default.
• W4379600227 hasVolume "40" @default.
• W4379600227 isParatext "false" @default.

• next